DXB (ASX) Ann: Quarterly Appendix 4C and Activities Report

Australia's largest stock trading and investment forum Australia's #1 stock forum

DXB

Click for more information

1.28%

38.5¢ dimerix limited

First 46 Last

Share
Profile

Follow
Malzo

794 Posts.

103

31/01/24

08:05

Post #: 72147085
Share

Originally posted by vrs37: ↑

"He’s implying that the because phase II trial had relatively few participants, it’s only really a Phase I."
wow, that's a truly idiotic misinterpretation of what I said.

// if they pass futility in a few weeks and the trial runs to the end as is designed and the endpoints are successful, agree it can satisfy NDA.
// If by accelerated approval you mean getting an approval before the end of the full trial based on just proteinuria result, then I reckon chances of that are slim to zero. it's very likely this trial will need to continue for the full 2 year follow up in all roughly 300 patients to get acceptable eGFR results, that's a few years away. if company had provided a recruitment update/forecast in the 4c as they really should have done imo, investors and analysts would have better idea of progress and likely trial completion time.
// and if they don't pass futility in a few weeks and trial folds, hard to see what the future is for this biotech as there is nothing else in their pipeline as far as I can see and this particular dmx2000 asset has no plausible alternative disease to pursue that I can see.

you can call this "trolling" , I really don't give a flying f##k, but this is how I see the situation , and so do others I've consulted on this.

Expand

DXB Price at posting: 22.0¢ Sentiment: None Disclosure: Held
3 Upvote

0 Great analysis

Reply

Top Stories

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

The market's shrugged at China's stimulus measures all year. Why is this one different?

NAM

ACCC seeks Olam divestments before it can buy Namoi Cotton

The winners & losers on market if negative gearing were gone

ESR

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Week 39 Wrap: What HotCopper’s watching; China’s new stimmy moves boost metals; Oz CPI drop

STK

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

KAL

KalGold rolls out detailed aeromagnetic survey across Pinjin project

DEG

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

There are more pages in this discussion • 14 more messages in this thread...

First 46 Last

Add DXB (ASX) to my watchlist

(20min delay)
Last 38.5¢		Change -0.005(1.28%)		Mkt cap ! $214.4M

Open	High	Low	Value	Volume
39.0¢	39.0¢	37.0¢	$503.5K	1.322M

Buyers (Bids)

No.	Vol.	Price($)
2	26318	38.0¢

Sellers (Offers)

Price($)	Vol.	No.
39.0¢	170072	6

View Market Depth

No.	Vol.	Price($)
2	26318	0.380
6	228354	0.375
6	178335	0.370
4	86518	0.365
4	27499	0.360

Price($)	Vol.	No.
0.390	170072	6
0.395	90849	3
0.400	144109	4
0.405	86528	4
0.410	56400	2

Last trade - 16.10pm 27/09/2024 (20 minute delay)

DXB (ASX) Chart

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

The market's shrugged at China's stimulus measures all year. Why is this one different?

ACCC seeks Olam divestments before it can buy Namoi Cotton

The winners & losers on market if negative gearing were gone

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Week 39 Wrap: What HotCopper’s watching; China’s new stimmy moves boost metals; Oz CPI drop

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

KalGold rolls out detailed aeromagnetic survey across Pinjin project

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Top Stories

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

The market's shrugged at China's stimulus measures all year. Why is this one different?

ACCC seeks Olam divestments before it can buy Namoi Cotton

The winners & losers on market if negative gearing were gone

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Week 39 Wrap: What HotCopper’s watching; China’s new stimmy moves boost metals; Oz CPI drop

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

KalGold rolls out detailed aeromagnetic survey across Pinjin project

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News